With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

The biotech is developing a Huntington’s disease (HD) gene therapy based on its proprietary capsid, AAV-DB-3. HD damages the neurons in the striatum, leading Latus to target the deep brain.

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Solid Biosciences (SLDB) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Pick the best stocks and maximize ...

Can you explain the purpose of the Vericheck ddPCR Empty-Full Capsid Kit and its role in AAV gene therapy? This kit is unique because it enables precise measurements, even at the crude lysate ...

In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit. The Vericheck ddPCR Empty-Full Capsid ...

Wedbush has assumed coverage of Voyager Therapeutics (VYGR) with an outperform rating, highlighting the company’s TRACER ...

MeiraGTx Holdings plc sees a stock surge after positive Parkinson's disease data and strategic partnerships, showing growth ...

Voyager's TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly ...